Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$110.31 - $140.45 $12.2 Million - $15.5 Million
110,568 Added 23.44%
582,199 $66 Million
Q1 2024

May 15, 2024

BUY
$114.22 - $140.1 $20.7 Million - $25.4 Million
181,631 Added 62.63%
471,631 $65.4 Million
Q4 2023

Feb 14, 2024

SELL
$75.49 - $124.16 $20.8 Million - $34.2 Million
-275,753 Reduced 48.74%
290,000 $36 Million
Q3 2023

Nov 14, 2023

BUY
$86.06 - $137.93 $35.8 Million - $57.3 Million
415,753 Added 277.17%
565,753 $52.8 Million
Q2 2023

Aug 14, 2023

SELL
$112.47 - $130.98 $21.4 Million - $24.9 Million
-190,000 Reduced 55.88%
150,000 $19.3 Million
Q1 2023

May 15, 2023

BUY
$104.0 - $122.92 $22.9 Million - $27 Million
219,920 Added 183.14%
340,000 $39.5 Million
Q4 2022

Feb 14, 2023

SELL
$84.98 - $122.67 $2.54 Million - $3.67 Million
-29,920 Reduced 19.95%
120,080 $13.6 Million
Q3 2022

Nov 14, 2022

SELL
$76.35 - $94.18 $26.7 Million - $33 Million
-350,000 Reduced 70.0%
150,000 $12.1 Million
Q2 2022

Aug 15, 2022

BUY
$67.99 - $132.89 $29.2 Million - $57.1 Million
430,000 Added 614.29%
500,000 $37.3 Million
Q1 2022

May 16, 2022

BUY
$94.08 - $130.2 $6.59 Million - $9.11 Million
70,000 New
70,000 $35.8 Million
Q1 2021

May 17, 2021

SELL
$84.79 - $104.74 $6.36 Million - $7.86 Million
-75,000 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$78.0 - $104.5 $5.85 Million - $7.84 Million
75,000 New
75,000 $27.7 Million
Q2 2020

Aug 14, 2020

SELL
$62.68 - $105.34 $1.25 Million - $2.11 Million
-20,000 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$47.79 - $75.63 $1.23 Million - $1.95 Million
-25,734 Reduced 56.27%
20,000 $5.39 Million
Q4 2019

Feb 14, 2020

BUY
$36.62 - $57.29 $1.67 Million - $2.62 Million
45,734 New
45,734 $10 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $30.9B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Iron Triangle Partners LP Portfolio

Follow Iron Triangle Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Iron Triangle Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Iron Triangle Partners LP with notifications on news.